Clinical trial provides preliminary evidence of a cure for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and Long Covid - BioSpace

 

BURLINGAME, Calif., Sept. 2, 2021 /PRNewswire/ -- Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS.  The company intends to test CT38 in Long Covid, the post-acute stage of COVID-19 infection, which is considered by many to be the latest trigger for ME/CFS.

Limbic System

Cortene believes the CRFR2 pathway is upregulated and therefore overactive, leading to the wide variety of symptoms in ME/CFS.  "The conventional approach would be to block the overactive pathway," said Sanjay Chanda, PhD, Cortene's Chief Development Officer.  "Instead, our counterintuitive approach seeks to overstimulate CRFR2, causing it to downregulate, without the need for chronic treatment."

CT38 was subcutaneously infused at one of four infusion rates for a maximum of 10.5 hours, in 14 ME/CFS patients.  CT38 treatment was safe and generally well-tolerated.  It was associated with significant reduction in mean 28-day, total daily symptom score (TDSS), which aggregated 13 patient-reported, daily symptom scores.  At an infusion rate of 0.03 μg/kg/h, mean TDSS improved by 26% (p < 0.01, n = 7).

"Infusing CT38 is known to cause temporary cardiovascular changes and InTiME revealed that patients were significantly more sensitive to these changes than healthy subjects from a previous safety study," said Hunter Gillies, MD, InTiME's medical monitor.  "These data support there being a pathological hypersensitivity in the CRFR2 pathway.  Given that InTiME showed i) dose-dependent improvements in TDSS; and ii) additional infusions provide additional benefit, the next trial should test CT38 using longer or additional infusions.  While infusion rates are somewhat limited by tolerability, it is total exposure at low rates that appears to drive symptom improvement."

"The persistent improvement in symptoms over weeks using a limited exposure is encouraging.  Many patients are still showing signs of improvement almost 2 years after treatment," said Lucinda Bateman, MD, founder and Medical Director of the Bateman Horne Center, scientific advisor to Cortene, and the Principal Investigator of the InTiME study.  "In fact, a few patients expressed a desire for 'just a little bit more drug'."

Full details of the trial have been peer reviewed and published in Frontiers in Systems Neuroscience, Acute corticotropin-releasing factor receptor type 2 agonism results in sustained symptom improvement in myalgic encephalomyelitis / chronic fatigue syndrome.  The publication explains how the CRFR2 pathway controls homeostasis (maintaining biological system stability), how this pathway can become disrupted at the neuronal level leading to the individual symptoms of ME/CFS and how these same symptoms manifest in many other chronic diseases.  Cortene plans to conduct additional trials in patients with ME/CFS and other diseases with similar symptoms using well-tolerated infusion rates and greater total exposure.

To view the full publication, please visit https://www.frontiersin.org/articles/10.3389/fnsys.2021.698240/full.

About ME/CFS
ME/CFS is an unexplained, life-long disease, usually triggered by infection, physical/mental trauma, or chemical exposure. Symptoms include diminished physical capacity, pain, sleep issues, cognitive impairment, orthostatic intolerance, among many others, which worsen with innocuous stimulation (referred to as post-exertional malaise) and are not improved by sleep. ME/CFS afflicts 3 million Americans. There are no approved therapeutics and quality of life is worse than in most chronic diseases.

About InTiME
InTiME was a proof-of-concept, single-site, open-label interventional trial, with patients blind as to dose, to investigate the safety and efficacy of CT38 in ME/CFS patients. Efficacy was assessed by a variety of endpoints, including patient-reported daily symptoms scores for each of 13 symptoms, general health (via SF-36), and continuous Fitbit™ monitoring. The primary endpoint was the change in the mean total daily symptom score over the 28-day periods immediately prior to the first treatment (pre-treatment) and immediately prior to exit from the trial (post-treatment).

About CT38
A proprietary peptide agonist, selective/specific for Corticotropin-Releasing Factor Receptor Type 2 (CRFR2).

About Cortene
Cortene Inc. (http://corteneinc.com, @CorteneInc) is a biopharmaceutical startup headquartered in Burlingame, CA, developing therapeutics for treating disorders related to disrupted homeostasis.

Contact: Michael Corbett, CBO, 408-373-7300, mcorbett@corteneinc.com, @CorteneInc on twitter.

Cortene Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-provides-preliminary-evidence-of-a-cure-for-myalgic-encephalomyelitis--chronic-fatigue-syndrome-mecfs-and-long-covid-301368121.html

SOURCE Cortene Inc.

 

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

Image
A Nova Scotia man is thanking a digital watch for saving his life. Travis Chalmers, of Elmsdale, N.S., said he was outside playing road hockey with his son when he suddenly experienced a "warm sensation" in his chest area and a splitting headache. "I just thought it was a flu or cold coming on and my seasonal allergies had been kicking in. I thought it was flu-like symptoms and shrugged it off," he said. But to Chalmers' surprise, an otherwise laidback afternoon eventually took a scary turn when he glanced at his wrist. A notification from his Apple Watch led him to discover he was experiencing a heart attack. "About a half hour later, I'm laying down with my daughter and my heart rate is still beating out of my chest," he continued, adding that he monitored his heart rate on his Apple Watch for the next few hours. The watch indicated that he was experiencing atrial fibrillation, a rapid heart rhythm that can increase the ris...
Read more

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w...
Read more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

Image
“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times Posted: 12 Dec 2019 11:25 AM PST It was chest pain that brought the 34-year-old woman to the emergency room at Montefiore Medical Center in the Bronx. She'd been coughing for days, but that morning the pain was so bad she was worried that it had turned into pneumonia. She tried to tough it out, but when it was no better by the end of the day, she decided to go to the E.R. It took a few hours, but finally the physician assistant caring for her in the E.R. brought some good news. She didn't have pneumonia; she didn't have a clot in her lungs. This was just muscle strain from coughing. The year before, she was told she had asthma. She was given inhalers to stop the coughing and wheezing, but they didn't seem to do much. So she didn'...
Read more